Table of Contents
March 23, 2021
Just a few days ago, the good news of a newborn who has “taken” the antibodies against the Sars-CoV-2 virus from the pregnant woman, vaccinated during pregnancy. It is a really beautiful story, which makes us understand how much and how science is moving forward in the challenge of the pandemic through immunization. And it’s a confirmation of how important vaccination is for protect the woman.
On the safety front, then, scientific societies take a position, in particular on the risk of thrombosis. The Italian Society of Gynecology and Obstetrics (SIGO), the Italian Hospital Obstetricians Gynecologists Association (AOGOI) and the Italian University Gynecologists Association (AGUI) have developed a document on anti-Covid vaccination19 and the (presumed) thrombotic risk at female, based on current knowledge. The document was also shared by the Italian Menopause Society (SIM), the Italian Society of Contraception (SIC) and the Italian Society of Gynecology for the Third Age (SIGITE).
There would be no increased risk
According to the experts, there is no data in the literature on the increased thrombotic risk in the population receiving the currently available Covid vaccines – including the AstraZeneca vaccine – compared to the general population, and there are no contraindications anti-Covid vaccination in women taking estrogen-progestogen contraceptives or using hormone replacement therapy.
“For these reasons – specify the gynecologists – vaccination is not an indication to carry out genetic investigations to assess the thrombophilic risk, nor to perform preliminary investigations or implement antithrombotic prophylaxis after vaccination”.
Specifically, the position paper, based on the data currently available from international experience and literature, reports some key points:
- there is no data in the literature that highlights an increase in thrombotic risk in the population subjected to the anti-Covid vaccine19, and in particular AstraZeneca, compared to the general population;
- the anti-Covid vaccine19 cannot therefore be considered a thrombotic risk factor to be added to any other anamnestic and personal risk factors that may be present;
- there is no contraindication to vaccination in women taking estrogen-progestins such as hormonal contraception or hormone replacement therapy;
- there is no indication to carry out preliminary investigations or to implement antithrombotic prophylaxis after vaccination;
- vaccination is not an indication for genetic testing to assess thrombophilic risk, nor is the desire for hormonal contraception;
- for non-pregnant women at increased thrombotic risk there is no evidence of contraindications to vaccination;
- women at increased thrombotic risk must undergo an antithrombotic prophylaxis personalized in relation to the risk during pregnancy and this condition does not contraindicate the vaccination against Covid-19.
Read also
